Monoclonal Antibody Therapeutics
•152 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (152)
| Company | Market Cap | Price |
|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is a monoclonal antibody therapeutic, placing Corbus in the monoclonal antibody therapeutics space.
|
$148.68M |
$11.91
-27.55%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$146.99M |
$1.48
-2.96%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$144.64M |
$0.24
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-1500 is a monoclonal antibody therapeutic, a core biologic drug candidate developed by Tonix.
|
$136.39M |
$18.65
+3.27%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$133.87M |
$2.19
-1.13%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 involves oral delivery of monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$126.59M |
$2.19
-0.68%
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$119.88M |
$14.00
|
|
AGEN
Agenus Inc.
Botensilimab (BOT) and balstilimab (BAL) are monoclonal antibody therapeutics targeting CTLA-4 and PD-1 pathways.
|
$108.84M |
$3.95
+3.67%
|
|
MGNX
MacroGenics, Inc.
MacroGenics has approved monoclonal antibody assets (MARGENZA, ZYNYZ, TZIELD) and focuses on monoclonal antibody therapeutics.
|
$104.73M |
$1.65
+3.45%
|
|
PLRX
Pliant Therapeutics, Inc.
PLN-101325 is a monoclonal antibody agonist targeting integrin α7β1, representing a direct antibody therapeutic program.
|
$103.13M |
$1.69
+2.74%
|
|
CNTX
Context Therapeutics Inc.
CTX's products are therapeutic antibodies (monoclonal antibody therapeutics) used for cancer.
|
$97.78M |
$1.08
-3.98%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$95.01M |
$1.71
-0.29%
|
|
STRO
Sutro Biopharma, Inc.
ADC therapies are a form of monoclonal antibody–based therapeutics, aligning with Sutro's antibody-drug conjugate products.
|
$94.60M |
$1.11
-3.88%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$91.97M |
$1.91
-0.78%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$85.97M |
$1.45
+9.47%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$85.19M |
$13.05
+0.89%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$78.80M |
$1.78
-7.29%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
FBIO
Fortress Biotech, Inc.
UNLOXCYT (cosibelimab-ipdl) asset involves a monoclonal antibody, fitting Monoclonal Antibody Therapeutics.
|
$75.70M |
$2.56
+0.20%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$71.65M |
$2.34
-0.43%
|
|
ANL
Adlai Nortye Ltd. American Depositary Shares
ANL’s antibody-based therapeutics position the company within Monoclonal Antibody Therapeutics as a related category.
|
$52.71M |
$1.42
-0.70%
|
|
EQ
Equillium, Inc.
Itolizumab is a monoclonal antibody therapeutic, mapping to Monoclonal Antibody Therapeutics.
|
$50.36M |
$1.44
+1.41%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$48.03M |
$1.56
+0.97%
|
|
FGEN
FibroGen, Inc.
FG-3246 utilizes a monoclonal antibody payload (YS5), aligning with Monoclonal Antibody Therapeutics.
|
$44.94M |
$11.12
+0.72%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium employs monoclonal antibodies (e.g., lintuzumab) as targeting components in its antibody-based radiotherapies.
|
$44.61M |
$1.42
|
|
LVTX
LAVA Therapeutics N.V.
The company focuses on antibody-based therapeutics (monoclonal antibody–type products) for cancer via its Gammabody platform.
|
$42.74M |
$1.62
-0.31%
|
|
OTLK
Outlook Therapeutics, Inc.
Bevacizumab is a monoclonal antibody; ONS-5010 is a monoclonal antibody therapeutic formulated for ophthalmic use.
|
$42.30M |
$1.27
+2.42%
|
|
XLO
Xilio Therapeutics, Inc.
Vilastobart is an anti-CTLA-4 monoclonal antibody, aligning with Monoclonal Antibody Therapeutics.
|
$41.25M |
$0.80
-0.13%
|
|
BCAB
BioAtla, Inc.
Evalstotug is a CAB-CTLA-4 antibody, a monoclonal antibody therapeutic.
|
$40.86M |
$0.70
+0.60%
|
|
AKTX
Akari Therapeutics, Plc
ADC uses monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$37.14M |
$0.76
+4.07%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Monoclonal antibody therapeutics tag reflects LIMN's lead anti-CD47 antibody program as a targeted biologic for cancer.
|
$36.16M |
$1.39
-1.77%
|
|
IKNA
Ikena Oncology, Inc.
IMG-007 is a monoclonal antibody therapeutic, placing the company in the Monoclonal Antibody Therapeutics category.
|
$35.03M |
$8.71
|
|
RADX
Radiopharm Theranostics Limited
Antibody-based therapeutics (PSA-mAb and B7-H3 mAb) used in radiopharmaceutical contexts.
|
$34.73M |
$5.30
+2.51%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$34.28M |
$2.83
+2.54%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$34.25M |
$2.26
-0.88%
|
|
DYAI
Dyadic International, Inc.
C1 platform has been used to produce monoclonal antibodies targeting RSV and malaria in legacy biopharma programs.
|
$34.00M |
$1.14
-2.56%
|
|
NXTC
NextCure, Inc.
ADCs are based on monoclonal antibodies delivering cytotoxic payloads, fitting the Monoclonal Antibody Therapeutics category.
|
$29.45M |
$12.62
+2.98%
|
|
RLYB
Rallybio Corporation
Lead programs are monoclonal antibody therapeutics (RLYB116 and RLYB332).
|
$29.02M |
$0.70
-0.06%
|
|
IBIO
iBio, Inc.
IBIO is developing monoclonal antibody therapeutics (e.g., IBIO-101, IBIO-600, Activin E antibodies).
|
$26.43M |
$1.59
-0.31%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$22.02M |
$1.40
+2.94%
|
|
KAPA
Kairos Pharma, Ltd.
ENV-105 is a monoclonal antibody therapeutic (CD105 antagonist) in development.
|
$19.04M |
$1.10
-2.21%
|
|
LPTX
Leap Therapeutics, Inc.
Its lead assets, sirexatamab (DKN-01) and FL-501, are monoclonal antibodies targeting cancer pathways.
|
$18.53M |
$0.45
-2.57%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$13.57M |
$0.42
+0.29%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$13.06M |
$1.74
-6.95%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Solnerstotug is a monoclonal antibody therapeutic targeting VISTA, aligning with Monoclonal Antibody Therapeutics.
|
$11.56M |
$9.15
-0.22%
|
|
BOLT
Bolt Biotherapeutics, Inc.
The company develops monoclonal antibody therapeutics (e.g., BDC-3042) as part of its ISAC platform.
|
$11.04M |
$5.80
+1.21%
|
|
IMRN
Immuron Limited
Antibody-based therapeutics (monoclonal antibody category) reflects Immuron's antibody-focused therapy approach.
|
$10.83M |
$1.91
-5.45%
|
|
CBIO
Crescent Biopharma, Inc.
The therapies are monoclonal antibody–based biologics, including antibody modalities.
|
$8.23M |
$12.79
+2.24%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$7.85M |
$2.94
-0.51%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaPro's high-affinity B7-H3 antibodies represent monoclonal antibody therapeutics.
|
$7.45M |
$11.83
+7.55%
|
|
HCWB
HCW Biologics Inc.
Second-generation pembrolizumab-based constructs and antibody-based ICIs fit Monoclonal Antibody Therapeutics.
|
$5.57M |
$3.88
-0.77%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$349274 |
$0.14
|
Showing page 2 of 2 (152 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
